Results 221 to 230 of about 253,625 (250)

Radium-223 in Prostate Cancer

New England Journal of Medicine, 2013
Hans-Jürgen, Biersack, Samer, Ezziddin, Furn F, Knapp   +2 more
openaire   +4 more sources

Real-world utilization patterns of radium-223 in metastatic prostate cancer in the United States: An administrative claims database study.

Journal of Clinical Oncology
79 Background: Radium (Ra)-223 is approved for use in men with symptomatic castration resistant prostate cancer (CRPC) with bone metastases, demonstrating benefits in terms of overall survival and quality of life with a reliable safety profile.
Amit D. Raval, Yiqiao Zhang, Matthew J. Korn, N. Constantinovici   +3 more
semanticscholar   +1 more source

Radium-223 beim Prostatakrebs

Info Onkologie, 2014
Fur Patienten mit metastasiertem kastrationsresistentem Prostatakrebs (mCRPC) ist Radium-223 eine interessante Option.
openaire   +1 more source

Assessing therapeutic response to Radium-223

Seminars in Nuclear Medicine
Radium-223 (223Ra), an alpha-emitting radiopharmaceutical targets bone and prolongs overall survival (OS) while reducing skeletal-related events (SREs) in metastatic castration-resistant prostate cancer patients (mCRPC). However, assessing 223Ra therapeutic response is difficult due to its distinct mechanism of action on bone remodeling and tumor ...
Caroline Torricelli, Ludmila Almeida, Elba Etchebehere   +2 more
openaire   +2 more sources

Radium-223

2014
Honecker, Friedemann, Wörmann, Bernhard, Schaefer, Reinhold, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss, Bokemeyer, Carsten, Heidenreich, Axel   +6 more
openaire   +1 more source

Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies.

European Urology Oncology
Michaela Lunan-Taylor, Amit D. Raval, Nguyen Thi Nhan Phan, Matthew J. Korn, Vanessa Quintero, R. McKay   +5 more
semanticscholar   +1 more source

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer

EClinicalMedicine, 2023
Oliver Sartor, Frank Verholen
exaly  

Radium 223 chloride

Reactions Weekly, 2015
openaire   +2 more sources

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer

Annals of Oncology, 2020
C N Sternberg, U N Vaishampayan, E Leung   +2 more
exaly  

Evaluation of optimal timing and therapeutic efficacy of radium-223 therapy for metastatic castration-resistant prostate cancer: a multicenter collaborative study.

Japanese Journal of Clinical Oncology
Fumihiko Urabe, Soshi Kadena, K. Tashiro, Kenichi Tokuoka, Y. Taneda, Kensuke Fujiwara, Yuma Goto, Juria Nakano, Shota Kawano, Yuya Iwamoto, Wataru Fukuokaya, Y. Imai, K. Iwatani, Mahito Atsuta, Kagenori Ito, T. Yanagisawa, Masaya Murakami, Shunsuke Tsuzuki, Toshihiro Yamamoto, Tatsuya Shimomura, J. Miki, Takahiro Kimura   +21 more
semanticscholar   +1 more source